mbs314
mAbexperimentalBi-specific
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 22, 2024 (NCT06232096)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
CD3E activator
- BCMAINHIBITOR
BCMA inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06232096 | Phase 1/Phase 2 (Phase 2) | Feb 22, 2024 | Beijing Mabworks Biotech Co., Ltd., China Academy of Chinese Medical Sciences |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Beijing Mabworks Biotech Co., Ltd. | For profit | 1 | 1 | 1 | 2024 |
| China Academy of Chinese Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1